Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PTI
- CUSIP: N/A
- Web: www.proteostasis.com
Capitalization:- Market Cap: $50.09 million
- Outstanding Shares: 25,101,000
Average Prices:- 50 Day Moving Avg: $3.38
- 200 Day Moving Avg: $7.20
- 52 Week Range: $1.94 - $18.99
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.87
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $7.94 million
- Price / Sales: 6.32
- Book Value: $2.04 per share
- Price / Book: 0.98
Profitability:- EBIDTA: ($52,450,000.00)
- Net Margins: -657.71%
- Return on Equity: -72.14%
- Return on Assets: -62.85%
Debt:- Current Ratio: 5.65%
- Quick Ratio: 5.65%
Misc:- Average Volume: 191,600 shs.
- Beta: 9.97
- Short Ratio: 3.97
Frequently Asked Questions for Proteostasis Therapeutics (NASDAQ:PTI)
What is Proteostasis Therapeutics' stock symbol?
Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."
How were Proteostasis Therapeutics' earnings last quarter?
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) issued its quarterly earnings data on Friday, May, 13th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.06. The firm earned $1.16 million during the quarter, compared to analyst estimates of $2.44 million. Proteostasis Therapeutics had a negative return on equity of 72.14% and a negative net margin of 657.71%. View Proteostasis Therapeutics' Earnings History.
Where is Proteostasis Therapeutics' stock going? Where will Proteostasis Therapeutics' stock price be in 2017?
3 equities research analysts have issued 1-year price objectives for Proteostasis Therapeutics' stock. Their predictions range from $9.00 to $15.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $12.33 in the next year. View Analyst Ratings for Proteostasis Therapeutics.
Who are some of Proteostasis Therapeutics' key competitors?
Some companies that are related to Proteostasis Therapeutics include MEI Pharma (MEIP), Galmed Pharmaceuticals (GLMD), Zafgen (ZFGN), Affimed N.V. (AFMD), Gemphire Therapeutics (GEMP), Applied Genetic Technologies Corporation (AGTC), Lipocine (LPCN), Pfenex (PFNX), Synthetic Biologics (SYN), ProNAi Therapeutics (SRRA), ADMA Biologics (ADMA), Ergomed PLC (ERGO), Intec Pharma (NTEC), Aldeyra Therapeutics (ALDX), ImmuPharma PLC (IMM), Flex Pharma (FLKS), Dicerna Pharmaceuticals (DRNA) and Dipexium Pharmaceuticals (PLXP).
Who are Proteostasis Therapeutics' key executives?
Proteostasis Therapeutics' management team includes the folowing people:
- M. James Barrett Ph.D., Independent Chairman of the Board
- Meenu Chhabra, President, Chief Executive Officer, Director
- Helen M. Boudreau, Chief Financial Officer, Principal Financial Officer, Treasurer
- Po-Shun Lee M.D., Executive Vice President, Chief Medical Officer
- Brett R. Hagen, Chief Accounting Officer, Vice President - Finance, Controller, Treasurer
- Benito Munoz, Chief Scientific Officer
- Janet L. Smart, Vice President - Intellectual Property & Legal Affaris
- Geoffrey S. Gilmartin M.D., Chief Development Officer
- Franklin M. Berger, Independent Director
- Jeffery W. Kelly Ph.D., Independent Director
When did Proteostasis Therapeutics IPO?
(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Who owns Proteostasis Therapeutics stock?
Proteostasis Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (14.20%), FMR LLC (11.76%), Jennison Associates LLC (8.29%), Hillhouse Capital Management Ltd. (3.45%), Marshall Wace North America L.P. (2.73%) and FIL Ltd (2.60%). Company insiders that own Proteostasis Therapeutics stock include Bioventures Ltd Novartis, Cormorant Asset Management, Ll, Enterprise Associates 12 New, Fmr Llc and Franklin M Berger. View Institutional Ownership Trends for Proteostasis Therapeutics.
Who sold Proteostasis Therapeutics stock? Who is selling Proteostasis Therapeutics stock?
Proteostasis Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Marshall Wace North America L.P., Vanguard Group Inc., Bank of New York Mellon Corp and TD Asset Management Inc.. View Insider Buying and Selling for Proteostasis Therapeutics.
Who bought Proteostasis Therapeutics stock? Who is buying Proteostasis Therapeutics stock?
Proteostasis Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, Jennison Associates LLC, FMR LLC, Dimensional Fund Advisors LP, Susquehanna International Group LLP, Goldman Sachs Group Inc. and LMR Partners LLP. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Bioventures Ltd Novartis, Cormorant Asset Management, Ll, Enterprise Associates 12 New and Franklin M Berger. View Insider Buying and Selling for Proteostasis Therapeutics.
How do I buy Proteostasis Therapeutics stock?
Shares of Proteostasis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteostasis Therapeutics' stock price today?
One share of Proteostasis Therapeutics stock can currently be purchased for approximately $2.00.
MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Proteostasis Therapeutics (NASDAQ:PTI)Earnings History by Quarter for Proteostasis Therapeutics (NASDAQ PTI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/13/2016 | Q2 | ($0.41) | ($0.47) | $2.44 million | $1.16 million | View | N/A |  |
| 7/25/2011 | | $0.11 | $0.29 | | | View | N/A | |
| 4/27/2011 | | $0.39 | $0.40 | | | View | N/A | |
| 2/9/2011 | | $0.37 | $0.49 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Proteostasis Therapeutics (NASDAQ:PTI)Current Year EPS Consensus Estimate: $-2.49 EPS
Next Year EPS Consensus Estimate: $-2.3 EPS
Dividend History for Proteostasis Therapeutics (NASDAQ:PTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Proteostasis Therapeutics (NASDAQ:PTI)Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 75.40%
Insider Trades by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/13/2017 | Fmr Llc | Insider | Sell | 25,000 | $12.94 | $323,500.00 | |
| 3/10/2017 | Fmr Llc | Insider | Sell | 25,000 | $12.04 | $301,000.00 | |
| 3/9/2017 | Fmr Llc | Insider | Sell | 29,300 | $12.08 | $353,944.00 | |
| 3/7/2017 | Fmr Llc | Insider | Sell | 60,000 | $13.01 | $780,600.00 | |
| 3/3/2017 | Fmr Llc | Insider | Sell | 45,000 | $13.91 | $625,950.00 | |
| 3/1/2017 | Fmr Llc | Insider | Sell | 45,000 | $14.62 | $657,900.00 | |
| 2/27/2017 | Fmr Llc | Insider | Sell | 28,000 | $14.60 | $408,800.00 | |
| 12/16/2016 | Franklin M Berger | Director | Buy | 40,000 | $11.17 | $446,800.00 | |
| 12/13/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 121,301 | $10.82 | $1,312,476.82 | |
| 12/8/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 44,417 | $10.83 | $481,036.11 | |
| 12/6/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 87,973 | $10.62 | $934,273.26 | |
| 12/1/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 170,391 | $10.24 | $1,744,803.84 | |
| 11/23/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 361,863 | $11.40 | $4,125,238.20 | |
| 11/14/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 259,500 | $11.05 | $2,867,475.00 | |
| 11/7/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 327,977 | $8.45 | $2,771,405.65 | |
| 9/14/2016 | Enterprise Associates 12 New | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | |
| 9/14/2016 | Franklin M Berger | Director | Buy | 69,230 | $13.00 | $899,990.00 | |
| 2/17/2016 | Bioventures Ltd Novartis | Major Shareholder | Buy | 375,000 | $8.00 | $3,000,000.00 | |
| 2/17/2016 | Franklin M. Berger | Director | Buy | 25,000 | $8.00 | $200,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Proteostasis Therapeutics (NASDAQ:PTI)
Latest Headlines for Proteostasis Therapeutics (NASDAQ:PTI)
| Source: |
|
| Date | Headline |
|---|
 | Proteostasis Therapeutics, Inc. (PTI) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - August 16 at 10:56 AM |
| $1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter
www.americanbankingnews.com - August 16 at 5:56 AM |
| Brokerages Anticipate Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to Announce -$0.61 EPS
www.americanbankingnews.com - August 14 at 8:04 PM |
 | Proteostasis Therapeutics (PTI) Names Helen M. Boudreau as CFO
www.streetinsider.com - August 1 at 4:03 AM |
 | Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer
finance.yahoo.com - August 1 at 4:03 AM |
| Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects
finance.yahoo.com - August 1 at 4:03 AM |
| Proteostasis Therapeutics, Inc. (PTI) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - July 12 at 11:50 AM |
| Zacks: Brokerages Expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Will Announce Quarterly Sales of $1.09 Million
www.americanbankingnews.com - July 5 at 11:04 AM |
| Proteostasis Therapeutics, Inc. (PTI) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - July 5 at 8:40 AM |
| -$0.63 EPS Expected for Proteostasis Therapeutics, Inc. (NASDAQ:PTI) This Quarter
www.americanbankingnews.com - July 3 at 12:40 PM |
| Proteostasis Therapeutics, Inc. (PTI) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - June 30 at 8:56 AM |
| Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
finance.yahoo.com - June 30 at 4:40 AM |
| Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator
finance.yahoo.com - June 23 at 9:17 AM |
| Proteostasis Therapeutics, Inc. (PTI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - June 17 at 10:58 PM |
| Proteostasis Therapeutics, Inc. (PTI) Short Interest Update
www.americanbankingnews.com - June 13 at 7:14 AM |
| Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
finance.yahoo.com - June 7 at 7:18 PM |
| -$0.59 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter
www.americanbankingnews.com - June 7 at 10:16 AM |
| ETFs with exposure to Proteostasis Therapeutics, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 8:00 PM |
| Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 10:06 PM |
| Zacks Investment Research Lowers Proteostasis Therapeutics Inc (PTI) to Hold
www.americanbankingnews.com - May 30 at 9:32 PM |
| Proteostasis Therapeutics Inc (PTI) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 28 at 7:18 AM |
| Proteostasis Therapeutics Inc (PTI) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 17 at 10:22 AM |
| ETFs with exposure to Proteostasis Therapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 6:36 PM |
| Brokerages Expect Proteostasis Therapeutics Inc (PTI) Will Announce Earnings of -$0.58 Per Share
www.americanbankingnews.com - May 11 at 2:14 PM |
| ETFs with exposure to Proteostasis Therapeutics, Inc. : May 1, 2017
finance.yahoo.com - May 1 at 6:40 PM |
| Proteostasis Therapeutics Inc (PTI) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 29 at 8:52 AM |
 | What's in Store for Merck (MRK) this Earnings Season?
www.nasdaq.com - April 26 at 5:54 PM |
| ETFs with exposure to Proteostasis Therapeutics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 7:27 PM |
| Brokerages Expect Proteostasis Therapeutics Inc (PTI) Will Post Earnings of -$0.58 Per Share
www.americanbankingnews.com - April 20 at 6:04 PM |
| ETFs with exposure to Proteostasis Therapeutics, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 6:54 PM |
| Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017
finance.yahoo.com - April 7 at 7:44 PM |
| Proteostasis Therapeutics Inc (PTI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 1:04 PM |
 | Proteostasis Therapeutics Inc. (PTI) Sank After Q4 Loss
www.rttnews.com - April 3 at 9:04 AM |
| Proteostasis Therapeutics' (PTI) Outperform Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - April 2 at 9:37 PM |
| Proteostasis Therapeutics Inc (PTI) Earns "Outperform" Rating from Robert W. Baird
www.americanbankingnews.com - April 2 at 9:07 PM |
| AEZS One Step Closer, AKTX To Report Data In April, CBIO On The Move
www.rttnews.com - March 31 at 8:32 AM |
 | BRIEF-Proteostasis Therapeutics reports Q4 loss per share $0.38
www.reuters.com - March 31 at 8:32 AM |
| Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
www.nasdaq.com - March 30 at 7:38 PM |
| PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosu
biz.yahoo.com - March 30 at 7:37 PM |
| Proteostasis Therapeutics Inc (PTI) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 29 at 11:31 PM |
| Proteostasis Therapeutics Inc (PTI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 25 at 2:39 PM |
| Proteostasis Therapeutics Inc (PTI) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 21 at 7:50 AM |
| Proteostasis Therapeutics Inc (PTI) Insider Fmr Llc Sells 25,000 Shares
www.americanbankingnews.com - March 15 at 7:45 PM |
| Form 8-K PROTEOSTASIS THERAPEUTIC For: Jan 09
www.streetinsider.com - January 10 at 1:05 AM |
| PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Dis
biz.yahoo.com - December 9 at 7:18 PM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Involving Possible Securities Fraud Violations by Proteostasis Therapeutics, Inc. and Certain ...
www.businesswire.com - October 29 at 6:34 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Involving Possible Securities Fraud Violations by Proteostasis Therapeutics, Inc. and Certain of Its Officers and Directors
finance.yahoo.com - October 28 at 6:43 PM |
 | Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference
globenewswire.com - October 27 at 11:53 AM |
| Form 8-K PROTEOSTASIS THERAPEUTIC For: Oct 27
www.streetinsider.com - October 27 at 11:53 AM |
| Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th …
finance.yahoo.com - October 27 at 11:53 AM |
Proteostasis Therapeutics (PTI) Chart for Sunday, August, 20, 2017
